Vaccine development is usually a long process and can take several years. However, the new COVID-19 vaccine was developed and approved for use in a matter of 8 months. This rapid timeline may sound alarming, but it was possible due to the large amount of funding, time and effort spent on research.
New vaccines go through different stages before being approved: preclinical trials and clinical trials (phases I, II and III). Preclinical trials involve testing the vaccine in cells and in animals. During phase I of clinical trials, the vaccine is given to a small number of healthy people. In phase II, the vaccine is given to more people who fit the characteristics of the intended target population. In phase III, the vaccine is given to thousands of people (usually 1,000 to 3,000) to test for effectiveness and safety.
The COVID-19 vaccine underwent the same rigorous testing as any other vaccine, but was fast-tracked by completing many stages at the same time. This means that all the usual safety checks were performed and completed simultaneously, rather than separately, saving a lot of time. The phase II/III trial of the new COVID-19 vaccine also had over 43,000 participants, which is far more than normally required.